Product
Lurasidone
Aliases
Latuda, Lurasidone HCl
Name
Latuda
INN Name
lurasidone hydrochloride
FDA Approved
Yes
11 clinical trials
1 organization
8 indications
1 document
Indication
Bipolar disorderIndication
Suicidal IdeationIndication
Suicidal Ideation and BehaviorIndication
SchizophreniaIndication
Bipolar I DepressionIndication
Bipolar DisorderIndication
Major Depressive DisorderIndication
PsychosisClinical trial
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind Controlled Comparison of NRX-101 to Lurasidone for Adults With Bipolar Depression and Subacute Suicidal Ideation or BehaviorStatus: Completed, Estimated PCD: 2024-02-28
Clinical trial
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine: An Open-label, Single-arm And Multi-center Study for 16 WeeksStatus: Terminated, Estimated PCD: 2022-11-18
Clinical trial
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia: A Multi-Center, Prospective, Open-Label Study for 6 WeeksStatus: Completed, Estimated PCD: 2023-04-16
Clinical trial
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia PatientsStatus: Completed, Estimated PCD: 2023-03-18
Clinical trial
Observational Study on the Effect of Switch to Lurasidone or Other Antipsychothics on Metabolic and Weight Changes in Subjects With Schizophrenia"Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
A Randomized, 6-Week, Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I DepressionStatus: Terminated, Estimated PCD: 2022-12-23
Clinical trial
Sleep Quality, Cognitive Performance, and Computerized Cognitive Training Comparison of Patients Treated With Lurasidone vs.Patients With Major Depression Receiving Selective Serotonin Reuptake Inhibitor(SSRI) Treatment as UsualStatus: Not yet recruiting, Estimated PCD: 2026-04-14
Clinical trial
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar DisorderStatus: Completed, Estimated PCD: 2019-08-01
Clinical trial
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)Status: Recruiting, Estimated PCD: 2024-01-28
Clinical trial
Longitudinal Comparative Effectiveness of Bipolar Disorder TherapiesStatus: Terminated, Estimated PCD: 2019-06-30
Document
DailyMed Label: LatudaOrganization
Sumitomo Pharma America, Inc.